Skip to content

Impairment Charges at other companies

Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.99B+351%

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ImpairmentOfLongLivedAssetsHeldForUse.

The official record: Taysha Gene Therapies, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Taysha Gene Therapies, Inc.'s impairment charges?
Taysha Gene Therapies, Inc. (TSHA) reported impairment charges of $0 in Q4 2025.
What does impairment charges mean?
Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.